bioAffinity Technologies publishes CyPath Lung case study showing 92% sensitivity in small nodules

bioAffinity Technologies, Inc.

CyPath Lung test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in nodules <2 cm.
Case study: 59-year-old with 30-year smoking history, COPD, multiple Lung-RADS 3 nodules; negative CyPath result.
Negative result allowed continued CT surveillance; follow-up CT showed stable nodules, avoiding invasive procedures.
Company markets test as LDT; case study reinforces clinical utility for reducing anxiety and supporting treatment decisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.